Nathalie Trépo
Contatto Relazioni con gli Investitori presso SparingVision SAS
Profilo
Nathalie Trépo is currently the Director-Investor Relations & Communications at SparingVision SAS since 2022.
Prior to this, she worked as the Head-Investor Relations at Theradiag SA and Neovacs SA.
Posizioni attive di Nathalie Trépo
| Società | Posizione | Inizio |
|---|---|---|
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Contatto Relazioni con gli Investitori | 01/02/2022 |
Precedenti posizioni note di Nathalie Trépo
| Società | Posizione | Fine |
|---|---|---|
| THERADIAG | Contatto Relazioni con gli Investitori | - |
| NEOVACS | Contatto Relazioni con gli Investitori | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NEOVACS | Health Technology |
| Aziende private | 2 |
|---|---|
Theradiag SA
 Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
- Borsa valori
- Insiders
- Nathalie Trépo